Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HHS “Unified Agenda” Shows FDA Is Behind On OTC Actions

This article was originally published in The Pink Sheet Daily

Executive Summary

More than half of OTC drug and dietary supplement action items in the FDA regulatory agenda are holdovers from the first half of the year. FDA intends to complete 15 OTC-related actions in the second half of the year.

You may also be interested in...

NDAC Approach To OTC Switches Highlighted At Corticosteroid Meeting

Panel review provides examples of different attitudes toward switches between OTC experts, other category-specific prescribers.

Plan B Decision Expected In Coming Weeks, Barr CEO Says

Downey says Rx sales of approximately $20 mil. have restricted availability of the emergency contraceptive at pharmacies across the country.

Topical Corticosteroid Adrenal Suppression Risk Precludes OTC Use, Advisory Committe Says

Topical corticosteroid HPA axis suppression risk under "maximal use conditions" should preclude the OTC marketing of the dermatologic products, FDA advisory committees say. Test for hypothalamus, pituitary, adrenal axis suppression is only 70% accurate, committee members note.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts